ERBB2 and breast carcinoma: Using ErbB2 monoclonal antibodies, typically trastuzumab (14), to block excess ErbB2 on the cell membrane and inhibit aberrant downstream signaling cascades represents the standard therapeutic option for ErbB2-overexpressing breast cancer patients (15).